Novartis shows continued commitment in Japan with Lucentis® approval in fourth Japanese indication, diabetic macular edema »

[at noodls] – Pivotal clinical data in Asian patients show a significant increase in mean visual acuity following treatment with Lucentis compared with laser therapy[1] Diabetic macular edema is a leading cause of blindness … more

View todays social media effects on NVS

View the latest stocks trending across Twitter. Click to view dashboard

See who Novartis is hiring next, click here to view